about
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesisVenous thromboembolism in cancer patients: an underestimated major health problemElevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma.Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancerHigh Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor ExtensionPerioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques.High D-dimer levels are associated with poor prognosis in cancer patientsComparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasisAssociation of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study.Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma.The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy.Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.Treatment of thromboembolism in cancer patients.Coagulation and cancer: biological and clinical aspects.Primary venous thromboembolism prophylaxis in ambulatory cancer patients.Coagulation and metastasis: what does the experimental literature tell us?Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer.Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography.LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer.The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression.Downregulation of Heparanase Expression Results in Suppression of Invasion, Migration, and Adhesion Abilities of Hepatocellular Carcinoma Cells.Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer.Understanding and treating solid tumor-related disseminated intravascular coagulation in the "era" of targeted cancer therapies.Preoperative plasma fibrinogen is associated with poor prognosis in esophageal carcinoma: a meta-analysis.Justification of routine venous thromboembolism prophylaxis in head and neck cancer reconstructive surgery.Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer.Primary melanoma tumor inhibits metastasis through alterations in systemic hemostasis.[Advances of tissue factor in lung cancer].Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 TrialMitral valve nonbacterial thrombotic endocarditis: a rare multi-surgery-tolerant survivor of Trousseau's syndrome
P2860
Q26740812-EE82680E-2C48-4C22-94AB-0DCE1F140073Q26852015-0A3A83F3-579C-4256-A45B-9931C354ACE4Q34565533-B4D60275-4E53-41EF-BD4F-E45901F721E1Q34607279-B0E0B87D-E9DD-4388-B674-D7636A8DBB91Q35529221-3C55EA29-701F-4DB7-AF92-4848C695A253Q35605876-EB1A0DF3-9605-449F-8C42-E6178983B9B8Q36133005-6DA67C43-9E51-4DF4-9040-BE07F9461C98Q36160668-6FD302BA-C266-4241-BE7B-5148A2ED6F1BQ36843779-87018092-77CA-4AF6-A90E-3B01B604639AQ37144916-A1115D16-8185-4AD7-BD49-D7E7491CB2DEQ37295308-00215BBC-0331-46EF-97AC-42A5C50BBFD2Q37662270-2379EF0D-FBD6-4485-8E47-C4C4669B1081Q37709136-A57ED710-4ED2-4551-B990-CCD10252C8E9Q37773994-071C25F7-9F56-434C-A265-3208886E7551Q38070918-ADA23C00-B8C9-4842-9E8B-2585FD6EF61CQ38079522-952103BF-ADA5-457C-83A5-0E28409CDDD2Q38108356-1C303820-93E2-460A-A2CD-B46E045A8883Q38232072-69E5E578-34D1-467E-B908-7EEC956442E7Q38674583-1561500F-9CA2-48B0-A533-1A5F9C74920CQ39379451-28D51BE8-7FC6-43B5-872E-396E05F22095Q39603869-0B1FB427-64A8-4B5B-8121-9522CB693650Q40217071-D47FA598-9259-442F-B0EC-B14CB8BD4601Q40489634-95294E3F-1664-43AF-A557-AF9F0BF57A4AQ41452973-AB942DDE-4722-432C-A5FD-BA8D39535A6EQ42161605-28195EBD-BC33-45BE-B492-F9D4757254B5Q43093333-609868BE-6B72-440A-AABA-0C3E460077D8Q45119447-54EF6202-CB2C-4CD7-B990-B36E5B2550F5Q47274345-5E2DFE11-36CD-4382-9E73-D51E6F27D6D1Q47841286-1F2E4AF8-C2DC-4920-BB37-6FAA7A4FEF51Q48265208-E1A94830-AD72-4ACF-BFEE-6F4D57E0A1C6Q53033345-6455E853-BCCE-466C-9D3E-3453CA128A80Q53129247-A5FFDAFE-5FA6-47F0-AE8E-B1A8D8C6EA1BQ55504653-3D3FA884-EB06-4398-9DAB-9E5EA31E8D77Q58129801-FF0410FE-C804-41C9-8EAF-3180F1A44285Q58695822-B8A89B0D-DFE3-4328-9453-1168A9D05C77
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Procoagulant mechanisms in tumour cells.
@en
Procoagulant mechanisms in tumour cells.
@nl
type
label
Procoagulant mechanisms in tumour cells.
@en
Procoagulant mechanisms in tumour cells.
@nl
prefLabel
Procoagulant mechanisms in tumour cells.
@en
Procoagulant mechanisms in tumour cells.
@nl
P1476
Procoagulant mechanisms in tumour cells
@en
P2093
Marina Panova-Noeva
P356
10.1016/J.BEHA.2008.12.009
P577
2009-03-01T00:00:00Z